SCHEMBL6541429

SCHEMBL6541429

COC(=O)CNCc1cc(OC(F)(F)F)ccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 8/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46
KCNH2 Q12809 2/20 0.44
CSNK1D P48730 1/20 0.44
CYP2D6 P10635 1/20 0.44
HTR1A P08908 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HRH1 P35367 1/20 0.44
HTR2B P41595 1/20 0.44
SLC6A3 Q01959 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6541423 0.99 TACR1 (0.48) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL15118586 0.79 KCNH2 (0.50) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL5598110 0.79 PPARG (0.50) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL21993472 0.78 PPARG (0.49) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL22220774 0.77 HCRTR1 (0.49) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL17764790 0.77 HSD17B10 (0.72) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL4638450 0.76 GRIN2B (0.46) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL5768808 0.76 TACR1 (0.50) TACR1PPARGPPARDPPARAKCNH2
SCHEMBL1269158 0.75 APLNR (0.71) HTR2AHTR2CMEN1KMT2AHDAC3
SCHEMBL28620798 0.74 ADRA1A (0.49) TACR1KCNH2CSNK1DCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787543-B2 PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-07 US disclosed
US-20030176430-A1 Benzhydryl derivatives ASTELLAS PHARMA INC. (JP) 2003-09-18 US disclosed
EP-1294700-A2 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-26 EP disclosed
WO-2002000631-A2 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176430-A1 Benzhydryl derivatives BDKRB1, BDKRB2, TACR1 TACR1 3/4885PPARG 3776/4885PPARD 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.